Objective:To investigate the correlation between preoperative plasma N-terminal pro-brain natriuretic peptide(NT-proBNP) and prognosis of cardiac resynchronization therapy as well as left ventricular function in patients with chronic heart failure.Methods:From March. 2012 to October.2014,60 patients who received CRT implantation in the first affiliated hospital,Nanjing Medical University were included. All the patients had the routine test contained NT-proBNP. Left ventricular ejection fraction(LVEF)were measured by echocardiography. The patients were divided into responders and non-responders according to whether the left ventricular ejection fraction (LVEF) increased ≥5% by 6 months. Major adverse cardiac events (MACE) was observed during follow-up. Results:Levels of NT-proBNP and MACE rates were much higher in non-responders than that in responders (P < 0.01). At the optimum cutoff point of 2 354.5 pg/mL,the sensitivity and specificity of NT-proBNP predicting CRT non-response were 95%and 92.5%,respectively.At the optimum cutoff point of 2 254.5 pg/mL,the sensitivity and specificity of NT-proBNP predicting MACE were 95.2% and 92.3%,respectively. Kaplan Meier survival curve showed the survival time in patients with BNP 2 254.5 pg/mL or less were higher than that in patients with BNP 2 254.5 pg/mL or more(P < 0.01). Conclusion:Preoperative NT-proBNP is associated with response to CRT and postoperative MACE in CHF patients.